Morgan Stanley Maintains Overweight on Eli Lilly and Co, Maintains $1023 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on Eli Lilly and Co (NYSE:LLY) with a $1023 price target.
July 05, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on Eli Lilly and Co (NYSE:LLY) with a $1023 price target.
The reaffirmation of an Overweight rating and a high price target of $1023 by a reputable analyst from Morgan Stanley is likely to positively influence investor sentiment and drive short-term price appreciation for Eli Lilly's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100